Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Intrauterine Insemination With Letrozole Versus in Natural Cycle
- First Posted Date
- 2018-03-06
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03455426
- Locations
- 🇨🇳
Peking University third Hospital, Beijing, Beijing, China
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant
- Conditions
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 287
- Registration Number
- NCT03439046
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Conditions
- Interventions
- Drug: CapecitabineDrug: AtezolizumabDrug: Ribociclib (dose #1)Drug: Inavolisib (dose #2)Drug: AbemaciclibDrug: Trastuzumab DeruxtecanDrug: IpatasertibDrug: Sacituzumab GovitecanDrug: FulvestrantDrug: Ribociclib (dose #2)Drug: Inavolisib (dose #1)Drug: SGN-LIV1ADrug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin)Drug: TocilizumabDrug: BevacizumabDrug: LetrozoleDrug: Nab-PaclitaxelDrug: InavolisibDrug: Selicrelumab
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 580
- Registration Number
- NCT03424005
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California San Diego Medical Center; Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
Different Methods of Termination of Second Trimester Abortion
- Conditions
- Interventions
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 150
- Registration Number
- NCT03400683
- Locations
- 🇪🇬
Kasr Alainy medical school, Cairo, Egypt
IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC
- Conditions
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Haukeland University Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT03378297
- Locations
- 🇳🇴
Helse Bergen HF, Haukeland University Hospital, Bergen, Norway
🇳🇴Helse Stavanger HF, Stavanger University Hospital, Stavanger, Norway
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Zhiyong Yu
- Target Recruit Count
- 200
- Registration Number
- NCT03373708
A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-10-11
- Last Posted Date
- 2024-01-30
- Target Recruit Count
- 198
- Registration Number
- NCT03306472
- Locations
- 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom
Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Greater Baltimore Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT03285802
- Locations
- 🇺🇸
Greater Baltimore Medical Center, Baltimore, Maryland, United States
Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Borstkanker Onderzoek Groep
- Target Recruit Count
- 100
- Registration Number
- NCT03283384
- Locations
- 🇳🇱
Catharina Ziekenhuis, Eindhoven, Netherlands
🇳🇱Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
🇳🇱Stichting Deventer Ziekenhuisgroep, Deventer, Netherlands
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Palleos Healthcare GmbH
- Target Recruit Count
- 257
- Registration Number
- NCT03272477
- Locations
- 🇩🇪
Evangelisches Krankenhaus Bethesda Mönchengladbach, Mönchengladbach, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.